“Many feel powerless in the face of unscrupulous corporate conduct, but the courtroom is one of the key venues in which meaningful relief can be achieved by those willing to engage in the necessary battles.”
Tyler is involved with most aspects of the firm’s practice. His current focus is on healthcare antitrust cases, but he has been brought into a number of matters involving product defects. Since joining the firm, Tyler has helped recover $9 million in overcharges paid by end-payors of Skelaxin.
He also helped in preparation for the trial for the In re Nexium Antitrust Litigation, the first ever pay-for-delay case to go to trial since the Supreme Court’s decision in FTC v. Actavis. Tyler has a special interest in the discovery of electronically stored information (ESI), and he is often consulted by members of the firm on ESI issues arising in their cases.
While in law school, Tyler served as the research assistant on projects related to the intersection of patent and antitrust laws and the obstacles to certifying indirect purchaser class actions. One research project explored issues of indirect purchaser standing in state antitrust suits, while the other focused specifically on the application of antitrust law and economics in the pharmaceutical industry.